May 7, 2018 / 12:17 PM / 7 months ago

BRIEF-Foamix Announces Dosing Of Last Patient In Third Phase 3 Acne Study

May 7 (Reuters) - Foamix Pharmaceuticals Ltd:

* FOAMIX ANNOUNCES DOSING OF LAST PATIENT IN THIRD PHASE 3 ACNE STUDY FOR MINOCYCLINE FOAM FMX101

* FOAMIX PHARMACEUTICALS LTD - TOP-LINE RESULTS EXPECTED IN Q3 OF 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below